埃索美拉唑辅助治疗反流性食管炎16例临床疗效观察

目的评价埃索美拉唑联合莫沙必利治疗反流性食管炎的临床疗效。方法将2010年2月至2013年3月来我院就诊的32例反流性食管炎患者随机分为两组，其中观察组16例，采用埃索美拉唑联合莫沙必利治疗，对照组16例，采用奥美拉唑联合莫沙必利治疗。观察并比较两组患者的临床疗效。结果观察组总有效率为93．75％，对照组总有效率为81．25％，两组比较差异有统计学意义，P〈0．05；两组患者治疗前主要症状积分相比差异无统计学意义，经治疗后，反酸、烧心、下咽困难及胸骨后疼痛的症状积分均较治疗前明显改善（P〈0．05）；观察组不良反应的发生率为6．25％，对照组不良反应的发生率为18．75％，差异有统计学意义，P〈0．05。结论埃索美拉唑联合莫沙必利治疗反流性食管炎疗效好，值得在临床上予以推广。

Clinical efficacy of esomeprazole auxiliary treatment of 16 cases of reflux esophagitis

Objective To evaluate the efficacy of esomeprazole combined with mosapride in the treatment of reflux esophagitis. Methods From February 2010 to March 2013, 32 patients with reflux esophagitis were randomly divided into two groups, 16 cases in each group. Observation group received esomeprazole and mosapride, while control group received omeprazole and mosapride. The efficacy of two groups was observed and compared. Results The total effective rate in observation group was 93.75%, that in control group was 81.25%, with statistical significant difference （P 〈 0.05）. There was no statistical significant difference in major symptom score between two groups before treatment; after treatment, symptom scores of acid reflux, heartburn, swallowing difficulty and retrosternal pain improved significantly （P 〈 0.05）. The incidence of adverse reactions in observation group was 6.25%, that in control group was 18.75%, with statistical significant difference （P 〈 0.05）. Conclusion Esomeprazole combined with mosapride in the treatment of reflux esophagitis is effective, worthy of clinical promotion.